Grifols : inaugurates a new plant of the Diagnostic Division in Brazil to manufacture storage and collection bags for blood components Download (60.9 Kb)

The company expands its presence in Latin America Grifols inaugurates a new plant in Brazil to manufacture storage and collection bags for blood components

• The new facility represents a Eur 16.5 million investment and is expected to begin operations in 2018. The project is currently in the approval stages.
• Located in Campo Largo (Paraná), the plant covers 5,525 m2 and has an initial production capacity of 2 million units expandable to 4 million units. When the plant becomes fully operational, it will create 150 jobs and serve as Grifols' sales subsidiary in Brazil.
• The inauguration was attended by the Spanish ambassador to Brazil and the prefect of Campo Largo, as well as other notable personalities. They were accompanied by the chairman and the co-CEOs of Grifols.

Barcelona (Spain), November 22, 2017.- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), one of the top three global producers of plasma-derived therapies and a forerunner in transfusional medicine, today announced the inauguration a new production plant in Brazil that will manufacture collection, separation, storage and transfusion bags for blood components, such as plasma, red blood cells and platelets. The production facility is currently in the approval stages and expected to become operative in 2018. It is located in Campo Largo, 20 kilometers from the center of Curitiba, the capital city of Paraná (Brazil).

The inauguration was attended by the Spanish ambassador to Brazil, Fernando Villalonga Campos, and the prefect of Campo Largo, Marcelo Puppi, as well as other notable personalities of public institutions from Brazil, who were accompanied by Víctor Grífols Roura, chairman of Grifols, and co-CEOs Raimon Grífols Roura and Víctor Grífols Deu, among other company representatives.

Grifols has allocated Eur 16.5 million to the project, which will allow the company to boost its presence in Latin America and meet the growing global demand for this type of product, developed by its Diagnostic Division.

More than 5,500 m2 of Grifols technology

The new 5,525-m2 site will be used to manufacture collection and storage bags for blood components. Production is scheduled to start in 2018. In an initial stage, the plant will have a dosage and assembly line with a total production capacity of 2 million kits per year, which will double in a second phase to reach 4 million. The Campo Largo facility currently employs 30 people, although its staff will grow to 150 when the site becomes fully operational. The industrial complex will also house Grifols' sales subsidiary in Brazil.

The facility was designed by Grifols Engineering, a company within the Grifols Group specialized in pharmaceutical and biotechnological engineering processes. The highly automated plant will integrate leading-edge in-house technology created by Grifols industrial complex in Murcia (Spain), where the company has three decades of experience manufacturing these products.

In order to meet the increasing demand in the Brazilian market and other Latin American countries for these products, the installations in Brazil and Spain will initially be complementary, although in the long term, both plants will operate as independent production units.

About Grifols

Grifols is a global healthcare company founded in 1940. Grifols has over 75 years improving people's health and wellbeing through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products.

The company is present in more than 100 countries worldwide and is headquartered in Barcelona, Spain. Grifols is a leader in plasma collection with a network of close to 180 plasma donor centers, and a leading producer of plasma-derived biological medicines. The company also provides a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks and transfusion centers, and is a recognized leader in transfusion medicine.

In 2016, sales exceeded 4,000 million euros with a headcount close to 15,000 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.

The company class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com

Investors contact: Investor Relations Department [e-mail] - [e-mail] Phone number: [phone] Media contact:

Raquel Lumbreras [e-mail] Borja Gómez [e-mail] Duomo Comunicación - Grifols Press Office

Phone number: [phone] - [phone]

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.